News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY) Schizophrenia Drug Fails Late-stage Trial


7/11/2012 8:34:12 AM

Eli Lilly and Co said on Wednesday its experimental schizophrenia drug known as mGlu2/3 did not work in a late stage clinical trial. The trial was intended to be the first of two late-stage tests of the drug as a stand-alone treatment in acute schizophrenia. A second trial is continuing and the company expects to conduct an interim analysis and present the results later this year. The company is also awaiting the results of a recently concluded mid-stage study examining the drug, also known as pomaglumetad methionil, as a combination treatment with existing drugs known as atypical antipsychotics.

Read at Reuters
Read at Nasdaq
Read at Market Watch
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES